Spinogenix Completes Phase 2 Enrollment for Schizophrenia Drug Tazbentetol — Spinogenix, Inc.

Event summary

Spinogenix completed enrollment in its Phase 2 trial for tazbentetol, a first-in-class synaptic regenerative therapy for schizophrenia, with 32 patients enrolled.
Interim results from the trial will be presented at the Schizophrenia International Research Society (SIRS) Annual Congress on March 26-29, 2026.
The trial evaluates tazbentetol's safety, efficacy, and pharmacodynamics in treating all three symptom domains of schizophrenia: positive, negative, and cognitive.
Primary endpoints include changes in PANSS Score and CGI-I, with EEG analysis and MCCB used for additional insights.

The big picture

Spinogenix's completion of Phase 2 enrollment for tazbentetol marks a significant step in the development of a potentially paradigm-shifting treatment for schizophrenia. The drug's unique mechanism of action, targeting synaptic regeneration, addresses a critical unmet need in managing negative and cognitive symptoms that current antipsychotics fail to treat effectively. The upcoming presentation of interim results at the SIRS Annual Congress will be a key milestone in assessing the therapeutic potential of tazbentetol and its impact on the schizophrenia treatment landscape.

What we're watching

Clinical Efficacy: Whether tazbentetol can demonstrate superior efficacy in addressing all three symptom domains of schizophrenia compared to existing treatments.
Regulatory Pathway: The pace at which Spinogenix can advance tazbentetol through subsequent clinical phases and secure regulatory approvals.
Market Differentiation: How Spinogenix positions tazbentetol in a competitive landscape dominated by antipsychotics that primarily target positive symptoms.